Edition:
United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

1.23USD
3:59pm EST
Change (% chg)

$0.01 (+0.82%)
Prev Close
$1.22
Open
$1.25
Day's High
$1.25
Day's Low
$1.20
Volume
17,948
Avg. Vol
26,750
52-wk High
$3.48
52-wk Low
$0.80

RPRX.OQ

Chart for RPRX.OQ

About

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally... (more)

Overall

Beta: -0.81
Market Cap(Mil.): $31.02
Shares Outstanding(Mil.): 25.43
Dividend: --
Yield (%): --

Financials

  RPRX.OQ Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.80 -- --
ROI: -120.84 -4.07 13.03
ROE: -120.84 4.71 14.17

BRIEF-Repros announces new CEO

* Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately Source text for Eikon: Further company coverage:

Feb 02 2017

BRIEF-Repros Therapeutics reports loss per share of $0.17

* Repros Therapeutics In Reports third quarter 2016 financial results

Nov 08 2016

BRIEF-Repros' secondary hypogonadism treatment filing accepted by European authorities

* Repros announces acceptance of dossier for Enclomiphene for secondary hypogonadism by European authorities

Oct 05 2016

BRIEF-Repros provides mid-stage results showing positive outcomes for oral Proellex

* Repros provides phase 2 results showing positive outcomes for oral Proellex in women with moderate to severe Endometriosis

Sep 07 2016

More From Around the Web

Earnings vs. Estimates